Inflammation and oxidative stress participate into the pathogenesis of cardiovascular and renal diseases. They are linked and closely related pathophysiological processes as well as able to regulate each other. Accumulating evidence demonstrates that increase ROS production and dysregulated inflammatory responses are associated with tissue damage and vascular and renal fibrosis. Indeed, numerous basic and translational studies revealed the potential tissue protective effects of antioxidant and anti-inflammatory pathways. Paradoxically, and despite this accumulating evidence, the development of effective of antioxidants and pharmacological approaches in humans to halt and prevent vascular and renal diseases has not been very successful.
The inflammasome and pyroptosis are emerging as major mechanisms involved in vascular and renal inflammation. Different studies suggest that attenuation of ROS production, directly by antioxidants or by the activation of antioxidant pathways, results in inflammasome and pyroptosis inhibition and may lead to the prevention of sustained tissue inflammation, oxidative stress, and end-organ damage.
This Research Topic will focus on molecular pathways, pharmacological approaches, genes and proteins involved in the regulation of vascular and renal oxidative stress and inflammation. These include pyroptosis, an inflammasome-dependent cell death pathway, and the inflammasome pathway as possible targets for the development of new therapies in cardiovascular disease.
Here, we welcome both original research and review articles.
Potential topics include, but are not limited to the following:
1. Cellular redox signalling in cardiovascular and renal cells: novel regulatory mechanisms of inflammation, inflammasome, oxidative stress, and pyroptosis;
2. Systemic redox signalling in renal disease: inflammation mechanisms, sex differences in inflammatory and stress response, inflammation and homeostasis in cardiovascular and renal functions;
3. Pharmacological approach: novel therapeutic agents or pharmacological inhibitors of oxidative stress, inflammation, fibrosis and inflammasome pathways and their potential therapeutic effects in cardiovascular and renal diseases
Inflammation and oxidative stress participate into the pathogenesis of cardiovascular and renal diseases. They are linked and closely related pathophysiological processes as well as able to regulate each other. Accumulating evidence demonstrates that increase ROS production and dysregulated inflammatory responses are associated with tissue damage and vascular and renal fibrosis. Indeed, numerous basic and translational studies revealed the potential tissue protective effects of antioxidant and anti-inflammatory pathways. Paradoxically, and despite this accumulating evidence, the development of effective of antioxidants and pharmacological approaches in humans to halt and prevent vascular and renal diseases has not been very successful.
The inflammasome and pyroptosis are emerging as major mechanisms involved in vascular and renal inflammation. Different studies suggest that attenuation of ROS production, directly by antioxidants or by the activation of antioxidant pathways, results in inflammasome and pyroptosis inhibition and may lead to the prevention of sustained tissue inflammation, oxidative stress, and end-organ damage.
This Research Topic will focus on molecular pathways, pharmacological approaches, genes and proteins involved in the regulation of vascular and renal oxidative stress and inflammation. These include pyroptosis, an inflammasome-dependent cell death pathway, and the inflammasome pathway as possible targets for the development of new therapies in cardiovascular disease.
Here, we welcome both original research and review articles.
Potential topics include, but are not limited to the following:
1. Cellular redox signalling in cardiovascular and renal cells: novel regulatory mechanisms of inflammation, inflammasome, oxidative stress, and pyroptosis;
2. Systemic redox signalling in renal disease: inflammation mechanisms, sex differences in inflammatory and stress response, inflammation and homeostasis in cardiovascular and renal functions;
3. Pharmacological approach: novel therapeutic agents or pharmacological inhibitors of oxidative stress, inflammation, fibrosis and inflammasome pathways and their potential therapeutic effects in cardiovascular and renal diseases